Abiopharma

(99% Neutral) Virios Therapeutics Inc. (VIRI) Announces Enrollment Update for license Due to Patient Enrollment Issues, Manufacturing Considerations

RenovoRx Expands RenovoCath® Commercial Adoption to Nine Active Cancer Centers Including City of Hope Cancer Center and Moffitt Cancer Center

Curaleaf Announces Strong Preliminary Unaudited Fourth Quarter 2025 Results

Volition Continues to Extend Access to Nu.Q® Vet Cancer Test

(99% Neutral) Coya Therapeutics Inc (COYA) Announces Clinical Development Update

New Form 424B5 - NovaBay Pharmaceuticals, Inc. Filed: 2026-01-20 AccNo: 0001437749-26-001489 Size: 498 KB

(99% Neutral) NovaBay Pharmaceuticals Inc. (NBY) Announces Business Combination

GSK plc (GLAXF) Files Form 6-K

LakeShore Biopharma Co., Ltd s (LSBPW) Files Form 6-K

(99% Neutral) CareCloud Inc (CCLDO) Provides Update on dividends for January

GSK plc (GLAXF) Files Form 6-K

(97% Neutral) Acadia Healthcare Company Inc (ACHC) Announces Business Combination

AstraZeneca Plc (AZNCF) Files Form 6-K

Dermata Receives Notice of Grant of Patent for Next-Generation Acne Treatment by Australian Patent Office

New Expert Consensus Published in The Laryngoscope Recommends PAPZIMEOS (zopapogene imadenovec) as the New Standard of Care First-Line Treatment for Adults with Recurrent Respiratory Papillomatosis